Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Burney Co.

Burney Co. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.9% in the 4th quarter, Holdings Channel reports. The fund owned 25,738 shares of the biopharmaceutical company’s stock after buying an additional 4,791 shares during the period. Burney Co.’s holdings in Alnylam Pharmaceuticals were worth $6,056,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Huntington National Bank grew its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at $29,000. Washington Trust Advisors Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, True Wealth Design LLC raised its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on ALNY. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Barclays boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Finally, Chardan Capital restated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $298.61.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,752 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at approximately $3,941,955. The trade was a 10.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,122 shares of company stock worth $2,540,455. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 2.8 %

NASDAQ ALNY opened at $247.33 on Wednesday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The business’s fifty day simple moving average is $248.15 and its 200-day simple moving average is $259.81. The firm has a market cap of $31.90 billion, a PE ratio of -94.40 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same quarter last year, the firm earned $1.15 EPS. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.